Skip to main content
. Author manuscript; available in PMC: 2024 Sep 19.
Published in final edited form as: Circulation. 2023 Aug 25;148(12):936–946. doi: 10.1161/CIRCULATIONAHA.123.064556

Figure 1. Cumulative Incidence for Bleeding Outcomes by Predicted Risk Category in The Development Cohorts: RE-LY and GARFIELD-AF.

Figure 1.

Figure 1.

Presented are the cumulative incidence curves for individuals in the development cohort (RE-LY trial) (1A) and the refinement cohort (GARFIELD-AF registry) (1B). Cumulative incidence curves were based on the risk category assigned to individuals by the DOAC Score. Risk-scores were 0-10, with risk categories assigned as: very low (score 0-3), low (score 4-5), moderate (score 6-7), high (score 8-9) and very high (score 10). Individuals in RE-LY were included if they were in the dabigatran 150 mg twice daily arm of the trial. Individuals in GARFIELD-AF were included if they were on any direct-acting oral anticoagulant (DOAC), irrespective of dose.

A) Cumulative Incidence for Major Bleeding by Risk Category in RE-LY

B) Cumulative Incidence for Major Bleeding by Risk Category in GARFIELD-AF